This study used a humanized anti-CD33 monoclonal antibody (HuM195) conjugated to the alpha-emitting isotope 213Bi to specifically target myeloid leukemia cells in patients who had acute myelogenous leukemia (AML) or chronic myelomonocytic leukemia [19]. The gene discussed is CD33; the disease is acute myeloid leukemia.